Efficacy of cariprazine in patients with bipolar depression and higher or lower levels of baseline anxiety: a pooled post hoc analysis.
Journal
International clinical psychopharmacology
ISSN: 1473-5857
Titre abrégé: Int Clin Psychopharmacol
Pays: England
ID NLM: 8609061
Informations de publication
Date de publication:
20 Sep 2023
20 Sep 2023
Historique:
pubmed:
8
8
2023
medline:
8
8
2023
entrez:
8
8
2023
Statut:
aheadofprint
Résumé
Post hoc analyses evaluated cariprazine, a dopamine D 3 -preferring D 3 /D 2 receptor partial agonist, in patients with bipolar I depression and high baseline anxiety. Data were pooled from two phase 3, randomized, double-blind, placebo-controlled studies in adults with bipolar I disorder and a major depressive episode (NCT02670538, NCT02670551). Cariprazine 1.5 and 3 mg/d were evaluated in patient subgroups with higher and lower baseline anxiety. In patients with higher baseline anxiety, significant differences for cariprazine 1.5 mg/d versus placebo were observed on change in Montgomery-Åsberg Rating Scale (MADRS) total score, Hamilton Anxiety Rating Scale (HAM-A) total score and subscale scores, and rates of MADRS remission ( P < 0.05 all); nonsignificant numerical improvements were observed for cariprazine 3 mg/d versus placebo. In patients with lower anxiety, differences versus placebo were significant for HAM-A (cariprazine 3 mg/d) and MADRS (cariprazine 1.5 and 3 mg/d) total score changes ( P < 0.05 all). Rates of treatment-emergent mania were low and similar for cariprazine and placebo. Cariprazine 1.5 mg/d had consistent effects on anxiety and depression symptoms in patients with bipolar I depression and higher baseline anxiety; tolerability was favorable. Given few proven treatments for this common comorbidity, these preliminary results are promising.
Identifiants
pubmed: 37551609
doi: 10.1097/YIC.0000000000000500
pii: 00004850-990000000-00081
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Adham N, Sághy K, Kiss B, Szombathelyi Z, Gyertyán I (2020). Anxiolytic-like activity of cariprazine, a dopamine D3 receptor-preferring antipsychotic, in rat models. Poster presented at: 59th Annual Meeting of the American College of Neuropsychopharmacology (virtual meeting); 6–9 December 2020.
APA. American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders. Fifth Edition. American Psychiatric Association.
Berry AS, White RL 3rd, Furman DJ, Naskolnakorn JR, Shah VD, D’Esposito M, et al. (2019). Dopaminergic mechanisms underlying normal variation in trait anxiety. J Neurosci 39:2735–2744.
Boylan KR, Bieling PJ, Marriott M, Begin H, Young LT, MacQueen GM (2004). Impact of comorbid anxiety disorders on outcome in a cohort of patients with bipolar disorder. J Clin Psychiatry 65:1106–1113.
Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162:1351–1360.
Celada P, Bortolozzi A, Artigas F (2013). Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs 27:703–716.
Cleary P, Guy W (1977). Factor analysis of the Hamilton depression scale. Drugs Exp Clin Res 1:115–120.
Cucchiaro J, Pikalov A, Hsu J, Kroger H, Loebel A (2014). Effect of lurasidone monotherapy or adjunctive therapy on anxiety symptoms in patients with bipolar I depression. Bipolar Disord 16(Suppl. 1):94. Abstract.
Dedic N, Kühne C, Jakovcevski M, Hartmann J, Genewsky AJ, Gomes KS, et al. (2018). Chronic CRH depletion from GABAergic, long-range projection neurons in the extended amygdala reduces dopamine release and increases anxiety. Nat Neurosci 21:803–807.
Durgam S, Earley W, Lipschitz A, Guo H, Laszlovszky I, Nemeth G, et al. (2016). An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry 173:271–281.
Duric V, Banasr M, Franklin T, Lepack A, Adham N, Kiss B, et al. (2017). Cariprazine exhibits anxiolytic and dopamine D3 receptor-dependent antidepressant effects in the chronic stress model. Int J Neuropsychopharmacol 20:788–796.
Earley W, Burgess MV, Rekeda L, Dickinson R, Szatmari B, Nemeth G, et al. (2019). Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study. Am J Psychiatry 176:439–448.
Earley WR, Burgess MV, Khan B, Rekeda L, Suppes T, Tohen M, et al. 2020a). Efficacy and safety of cariprazine in bipolar I depression: a double-blind, placebo-controlled phase 3 study. Bipolar Disord 22:372–384.
Earley WR, Burgess M, Rekeda L, Hankinson A, McIntyre RS, Suppes T, et al. 2020b). A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression. J Affect Disord 263:386–395.
Fornaro M, De Berardis D, Koshy AS, Perna G, Valchera A, Vancampfort D, et al. (2016). Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review. Neuropsychiatr Dis Treat 12:719–735.
Fornaro M, Anastasia A, Novello S, Fusco A, Solmi M, Monaco F, et al. (2018). Incidence, prevalence and clinical correlates of antidepressant-emergent mania in bipolar depression: a systematic review and meta-analysis. Bipolar Disord 20:195–227.
Fung VC, Overhage LN, Sylvia LG, Reilly-Harrington NA, Kamali M, Gao K, et al. (2019). Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors. J Affect Disord 257:17–22.
Gao K, Wu R, Kemp DE, Chen J, Karberg E, Conroy C, et al. (2014). Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: a randomized, placebo-controlled trial. J Clin Psychiatry 75:1062–1068.
Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, et al. (2020). Pharmacotherapy of anxiety disorders: current and emerging treatment options. Front Psychiatry 11:595584.
Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E (2000). Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 283:3082–3088.
Girgis RR, Slifstein M, D’Souza D, Lee Y, Periclou A, Ghahramani P, et al. (2016). Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO. Psychopharmacology (Berl) 233:3503–3512.
Hamilton M (1959). The assessment of anxiety states by rating. Br J Med Psychol 32:50–55.
Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62.
Hirschfeld RM, Weisler RH, Raines SR, Macfadden W, Group BS (2006). Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 67:355–362.
Keller MB (2006). Prevalence and impact of comorbid anxiety and bipolar disorder. J Clin Psychiatry 67(Suppl 1):5–7.
Kienast T, Hariri AR, Schlagenhauf F, Wrase J, Sterzer P, Buchholz HG, et al. (2008). Dopamine in amygdala gates limbic processing of aversive stimuli in humans. Nat Neurosci 11:1381–1382.
Li F, Nasir M, Olten B, Bloch MH (2019). Meta-analysis of placebo response in adult antidepressant trials. CNS Drugs 33:971–980.
Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, et al. 2014a). Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 171:169–177.
Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, et al. 2014b). Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry 171:160–168.
Lydiard RB, Culpepper L, Schioler H, Gustafsson U, Paulsson B (2009). Quetiapine monotherapy as treatment for anxiety symptoms in patients with bipolar depression: a pooled analysis of results from 2 double-blind, randomized, placebo-controlled studies. Prim Care Companion J Clin Psychiatry 11:215–225.
McIntyre RS, Calabrese JR (2019). Bipolar depression: the clinical characteristics and unmet needs of a complex disorder. Curr Med Res Opin 35:1993–2005.
McIntyre R, Katzman M (2003). The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar Disord 5(Suppl 2):20–35.
McIntyre RS, Masand PS, Earley W, Patel M (2019). Cariprazine for the treatment of bipolar mania with mixed features: a post hoc pooled analysis of 3 trials. J Affect Disord 257:600–606.
McIntyre RS, Berk M, Brietzke E, Goldstein BI, Lopez-Jaramillo C, Kessing LV, et al. (2020). Bipolar disorders. Lancet 396:1841–1856.
Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. (2011). Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 68:241–251.
Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389.
Otto MW, Simon NM, Wisniewski SR, Miklowitz DJ, Kogan JN, Reilly-Harrington NA, et al.; STEP-BD Investigators (2006). Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br J Psychiatry 189:20–25.
Patel M, Jain R, Tohen M, Maletic V, Earley WR, Yatham LN (2021). Efficacy of cariprazine in bipolar I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies. Int Clin Psychopharmacol 36:76–83.
Pavlova B, Perlis RH, Alda M, Uher R (2015). Lifetime prevalence of anxiety disorders in people with bipolar disorder: a systematic review and meta-analysis. Lancet Psychiatry 2:710–717.
Penninx BW, Pine DS, Holmes EA, Reif A (2021). Anxiety disorders. Lancet 397:914–927.
Pies R (2009). Should psychiatrists use atypical antipsychotics to treat nonpsychotic anxiety? Psychiatry (Edgmont) 6:29–37.
Pignon B, Tezenas du Montcel C, Carton L, Pelissolo A (2017). The place of antipsychotics in the therapy of anxiety disorders and obsessive-compulsive disorders. Curr Psychiatry Rep 19:103.
Rakofsky JJ, Dunlop BW (2011). Treating nonspecific anxiety and anxiety disorders in patients with bipolar disorder: a review. J Clin Psychiatry 72:81–90.
Sala R, Goldstein BI, Morcillo C, Liu SM, Castellanos M, Blanco C (2012). Course of comorbid anxiety disorders among adults with bipolar disorder in the U.S. population. J Psychiatr Res 46:865–872.
Salem H, Nagpal C, Pigott T, Teixeira AL (2017). Revisiting antipsychotic-induced akathisia: Current issues and prospective challenges. Curr Neuropharmacol 15:789–798.
Schaffer A, McIntosh D, Goldstein BI, Rector NA, McIntyre RS, Beaulieu S, et al.; Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force (2012). The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry 24:6–22.
Sheehan DV, McElroy SL, Harnett-Sheehan K, Keck PE Jr, Janavs J, Rogers J, et al. (2009). Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. J Affect Disord 115:376–385.
Simon NM, Otto MW, Wisniewski SR, Fossey M, Sagduyu K, Frank E, et al. (2004). Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 161:2222–2229.
Stahl SM, Laredo S, Morrissette DA (2020). Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data. Ther Adv Psychopharmacol 10:2045125320905752.
Steiner H, Fuchs S, Accili D (1997). D3 dopamine receptor-deficient mouse: evidence for reduced anxiety. Physiol Behav 63:137–141.
Suppes T, McElroy SL, Sheehan DV, Hidalgo RB, Cosgrove VE, Gwizdowski IS, et al. (2014). A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder. J Clin Psychiatry 75:77–84.
Sylvia LG, Montana RE, Deckersbach T, Thase ME, Tohen M, Reilly-Harrington N, et al. (2017). Poor quality of life and functioning in bipolar disorder. Int J Bipolar Disord 5:10.
Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, et al.; BOLDER II Study Group (2006). Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 26:600–609.
Tohen M, Calabrese J, Vieta E, Bowden C, Gonzalez-Pinto A, Lin D, et al. (2007). Effect of comorbid anxiety on treatment response in bipolar depression. J Affect Disord 104:137–146.
Vieta E, Durgam S, Lu K, Ruth A, Debelle M, Zukin S (2015). Effect of cariprazine across the symptoms of mania in bipolar I disorder: analyses of pooled data from phase II/III trials. Eur Neuropsychopharmacol 25:1882–1891.
Yapici Eser H, Kacar AS, Kilciksiz CM, Yalçinay-Inan M, Ongur D (2018). Prevalence and associated features of anxiety disorder comorbidity in bipolar disorder: a meta-analysis and meta-regression study. Front Psychiatry (Systematic Review) 9:229.
Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 20:97–170.
Yatham LN, Vieta E, McIntyre RS, Jain R, Patel M, Earley W (2020). Broad efficacy of cariprazine on depressive symptoms in bipolar disorder and the clinical implications. Prim Care Companion CNS Disord 22:20m02611.
Young RC, Biggs JT, Ziegler VE, Meyer DA (1978). A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429–435.